Extrapyramidal reactions associated with serotonergic antidepressants

Annals of Pharmacotherapy

Volumn 49, Issue 10, 2015, Pages 1136-1152

  Hawthorne, Jessica M ^a   Caley, Charles F ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Akathisia; Antidepressive agents; Dyskinesia; Dystonia; Humans; Parkinsonism; Serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; SEROTONERGIC ANTIDEPRESSANT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNCLASSIFIED DRUG; VENLAFAXINE; ADRENERGIC RECEPTOR AFFECTING AGENT; NEUROLEPTIC AGENT;

AKATHISIA; DATA EXTRACTION; DRUG DOSE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; MEDICAL LITERATURE; NARANJO ADVERSE DRUG REACTION PROBABILITY SCALE; PARKINSONISM; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RATING SCALE; REVIEW; AGE; AKATHISIA, DRUG-INDUCED; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; EXTRAPYRAMIDAL SYSTEM; FEMALE; MALE; PARKINSON DISEASE, SECONDARY; PATHOPHYSIOLOGY; PSYCHOMOTOR AGITATION; RISK FACTOR; SEX DIFFERENCE;

ADRENERGIC UPTAKE INHIBITORS; AGE FACTORS; AKATHISIA, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; EXTRAPYRAMIDAL TRACTS; FEMALE; HUMANS; MALE; PARKINSON DISEASE, SECONDARY; PSYCHOMOTOR AGITATION; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 84951157849     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015594812     Document Type: Review

References (107)

1. deVerteuil RL, Lehmann HE. Therapeutic trial of iproniazid (Marsilid) in depressed and apathetic patients. CMAJ. 1958;78:131-133.
2. Foster AR, Lancaster NP. Disturbance of motor function during treatment with imipramine. Br Med J. 1959;2: 1452-1453.
3. Lancaster NP, Foster AR. Suicidal attempt by imipramine overdosage [letter]. Br Med J. 1959;2:1458.
4. Fann WE, Sullivan JL, Richman BW. Dyskinesias associated with tricyclic antidepressants. Br J Psychiatry. 1976;128: 490-493.
5. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry. 1992;53:278-282.
6. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57: 449-454.
7. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997;17:377-389.
8. Caley CF. Extrapyramidal reactions and the selective serotonin reuptake inhibitors. Ann Pharmacother. 1997;31: 1481-1489.
9. Gerber PE, Lynd LE. Selective serotonin-reuptake inhibitor induced movement disorders. Ann Pharmacother. 1998;32:692-698.
10. Govoni S, Racchi M, Masoero E, Zamboni M, Ferini-Strambi L. Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly. Mol Psychiatry. 2001;6:134-142.
11. Schillevoort I, van Puijenbroek EP, de Boer A, Roos RA, Jansen PA, Leufkens HG. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol. 2002;17:75-79.
12. Gony M, Lapeyre-Mestre M, Montastruc JL; French Network of Regional Pharmacovigilance Centers. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol. 2003;26:142-145.
13. Draper B, Berman K. Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly. Drugs Aging. 2008;25:501-519.
14. Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants- a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry. 2010;22:148-156.
15. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466-476.
16. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora AC. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm. 1979;45:165-175.
17. Tzallas PJ, Rynn KO. Extrapyramidal side effects secondary to venlafaxine [abstract 82]. Toxicol Clin Toxicol. 1995;33:518.
18. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
19. Kuo FJ, Lane HY, Chang WH. Extrapyramidal symptoms after addition of fluvoxamine to clozapine. J Clin Psychopharmacol. 1998;18:483-484.
20. Boffa E, Lofchy J. Paroxetine and tardive akathisia. Can J Psychiatry. 2000;45:398.
21. Hansen L, Wilkinson DG. Drug induced akathisia, suicidal ideation and its treatment in the elderly. Int J Geriatr Psychiatry. 2001;16:231-233.
22. Hensley PL, Reeve A. A case of antidepressant-induced akathisia in a patient with traumatic brain injury. J Head Trauma Rehabil. 2001;16:302-305.
23. Chelben J, Strous RD, Lustig M, Baruch Y. Remission of SSRI-induced akathisia after switch to nefazodone. J Clin Psychiatry. 2001;62:570-571.
24. Akagi H, Kumar TM. Lesson of the week. Akathisia: overlooked at a cost. BMJ. 2002;324:1506-1507.
25. Buchman N, Strous RD, Baruch Y. Side effects of long-term treatment with fluoxetine. Clin Neuropharmacol. 2002;25: 55-57.
26. Hansen L. Fluoxetine dose-increment related akathisia in depression: Implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia. J Psychopharmacol. 2003;17:451-452.
27. Cohen ST, Rulf D, Pies R. Extrapyramidal side effects associated with aripiprazole coprescription in 2 patients. J Clin Psychiatry. 2005;66:135-136.
28. Nishida T, Wada M, Wada M, Ito H, Narabayashi M, Onishi H. Activation syndrome caused by paroxetine in a cancer patient. Palliat Support Care. 2008;6:183-185.
29. Muhtz C, Agorastos A, Kellner M. Acute maniform reaction to a single dose of escitalopram in a social phobic patient- an atypical jitteriness syndrome? Pharmacopsychiatry. 2009;42:291-292.
30. George M, Campbell JJ 3rd. Venlafaxine causing akathisia: a case report. J Neuropsychiatry Clin Neurosci. 2012;24(3): E3-E4.
31. Imboden C, Hatzinger M. Agomelatine-induced akathisia with concomitant duloxetine medication: a case report. Pharmacopsychiatry. 2012;45:162-163.
32. Lai CH. Venlafaxine-related akathisia side-effects and management in a depressed patient. Psychiatry Clin Neurosci. 2013;67:127-128.
33. Grover S, Valaparla VL. Venlafaxine induced akathisia: a case report. Indian J Pharmacol. 2014;46:660-661.
34. Friedman JH. Rapid onset tardive dyskinesia ("fly catcher tongue") in a neuroleptically naive patient induced by risperidone. Med Health R I. 1998;81:271-272.
35. Nielsen AS, Mors O. Choreiform dyskinesia with acute onset and protracted course following fluoxetine treatment. J Clin Psychiatry. 1999;60:868-869.
36. Lee MS, Nam JW. A case of paroxetine-induced dyskinetic movements. J Clin Psychopharmacol. 2000;20:712-713.
37. Albertini G, Majolini L, Di Gennaro G, et al. Oral dyskinesia induced by fluoxetine therapy for infantile autism. Pediatr Neurol. 2004;31:76.
38. Carluer L, Schupp C, Defer GL. Ear dyskinesia. J Neurol Neurosurg Psychiatry. 2006;77:802-803.
39. Deuschle M, Mase E, Zink M. Dyskinesia during treatment with duloxetine. Pharmacopsychiatry. 2006;39:237-238.
40. Bond GR, Garro AC, Gilbert DL. Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clin Toxicol (Phila). 2007;45:182-185.
41. Lee Y, Yeh WC, Chong MY, Lin PY, Chang YY. Venlafaxine and tardive blepharospasm: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1139-1140.
42. Duggal HS, Mendhekar DN. A case report of reemergence of antipsychotic-induced dyskinesia with citalopram. J Clin Psychiatry. 2007;68:803.
43. Jakob F, Wolf J. EPMS under antidepressive therapy with fluvoxamine and concomitant antibiotic therapy with clindamycin. Pharmacopsychiatry. 2007;40:129.
44. Ghanizadeh A. Sertraline and tic: case report. Pharmacopsychiatry. 2007;40:289-290.
45. Huther R, Gebhart C, Mirisch S, Bauml J, Forstl H. Choreatic symptoms during and after treatment with paliperidone and escitalopram. Pharmacopsychiatry. 2008;41:203-204.
46. Park YM, Lee HJ, Kang SG, Choo CS, Cho JH. Tardive dyskinesia associated with long-term administration of escitalopram and itopride in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:380-381.
47. Bhakta SG, Andrade C. Melatonin treatment of shoulderand- neck dyskinesia possibly related to fluoxetine treatment. World J Biol Psychiatry. 2009;10(4 pt 3):1047-1048.
48. Muthusami S, Basu S, Kumar A, Dash A. Acute dyskinesia and extrapyramidal disorder in a child after ingestion of escitalopram. J Child Adolesc Psychopharmacol. 2009;19:317-318.
49. Ng J, Sansone RA, McDonald S. Akathisia and abnormal movements of the upper extremities with venlafaxine and methimazole. Gen Hosp Psychiatry. 2009;31:388-390.
50. Birthi P, Walters C, Karandikar N. A rare case of tardive dyskinesia and akathisia induced by citalopram. PM R. 2010;2:973-975.
51. Albayrak Y, Ekinci O. Duloxetine-associated tardive dyskinesia resolved with fluvoxamine: A case report. J Clin Psychopharmacol. 2012;32:723-724.
52. Palop V, Jimenez MJ, Catalan C, Martinez-Mir I. Acute dystonia associated with fluvoxamine-metoclopramide. Ann Pharmacother. 1999;33:382.
53. Mathen D, Marsden CD, Bhatia KP. SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia. Mov Disord. 1999;14:874-876.
54. Lenti C. Movement disorders associated with fluvoxamine. J Am Acad Child Adolesc Psychiatry. 1999;38:942-943.
55. Patel OP, Simon MR. Oculogyric dystonic reaction to escitalopram with features of anaphylaxis including response to epinephrine. Int Arch Allergy Immunol. 2006;140:27-29.
56. Dominguez-Moran JA, Callejo JM, Fernandez-Ruiz LC, Martinez-Castrillo JC. Acute paroxysmal dystonia induced by fluoxetine. Mov Disord. 2001;16:767-769.
57. Teoh L, Allen H, Kowalenko N. Drug-induced extrapyramidal reactions. J Paediatr Child Health. 2002;38:95-97.
58. Walker L. Sertraline-induced akathisia and dystonia misinterpreted as a panic attack. Psychiatr Serv. 2002;53: 1477-1478.
59. Arnone D, Hansen L, Kerr JS. Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care. J Psychopharmacol. 2002;16:395-397.
60. Najjar F, Price LH. Citalopram and dystonia. J Am Acad Child Adolesc Psychiatry. 2004;43:8-9.
61. Parvin MM, Swartz CM. Dystonic rabbit syndrome from citalopram. Clin Neuropharmacol. 2005;28:289-291.
62. Yumru M, Savas HA, Selek S, Savas E. Acute dystonia after initial doses of ziprasidone: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30: 745-747.
63. Sanghadia M, Pinninti NR. Aripiprazole-associated acute dystonia. J Neuropsychiatry Clin Neurosci. 2007;19:89-90.
64. Brahm NC, McElwain DL, Brown RC. Potential aripiprazole- mediated extrapyramidal symptoms in an adult with developmental disabilities. Am J Health Syst Pharm. 2007;64:827-829.
65. Garcia Ruiz PJ, Cabo I, Bermejo PG, Carnal P. Escitalopraminduced paroxysmal dystonia. Clin Neuropharmacol. 2007; 30:124-126.
66. Bilen S, Saka M, Ak F, Oztekin N. Persistent dystonia induced by fluoxetine. Intern Med J. 2008;38:672-674.
67. Fonseca L, Rodrigues M, Machado A. Psychogenic movement disorder after a venlafaxine-induced dystonia. Mov Disord. 2010;25:506-507.
68. Hood S, Orr K, Bennett L, Davies S. Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. Australas Psychiatry. 2010;18:174-176.
69. Chen PY, Lin PY, Tien SC, Chang YY, Lee Y. Duloxetinerelated tardive dystonia and tardive dyskinesia: a case report. Gen Hosp Psychiatry. 2010;32:646. e9-646. e11.
70. Perrone V, Antoniazzi S, Carnovale C, et al. A case of Pisa syndrome during sertraline and quetiapine treatment. J Neuropsychiatry Clin Neurosci. 2012;24(3):E31-E32.
71. Oulis P, Konstantakopoulos G, Nathanailidis E, Tsiamoura M, Kollias K. Low-dose aripiprazole in the treatment of selective serotonin reuptake inhibitors-induced orofacial and buccal dystonia. Psychiatry Clin Neurosci. 2012;66: 462-463.
72. Karakas Ugurlu G, Onen S, Bayindirli D, Caykoylu A. Acute dystonia after using single dose duloxetine: case report. Psychiatry Investig. 2013;10:95-97.
73. Paul S, Cooke BK, Nguyen M. Glossopharyngeal dystonia secondary to a lurasidone-fluoxetine CYP-3A4 interaction. Case Rep Psychiatry. 2013;2013:136194.
74. Tikka SK, Garg S, Das B. Fluvoxamine induced oculogyric dystonia and manic switch in a patient with obsessive compulsive disorder. Indian J Pharmacol. 2013;45:532-533.
75. Nimber JS, Aggarwal A. Acute extrapyramidal syndrome induced by escitalopram: a case report [letter]. Psychopharmacol (Berlin). 2014;231:3813-3814.
76. Morgan RJ, Dolenc TJ. Escitalopram-induced progressive cervical dystonia [published online December 5, 2014]. Psychosomatics. doi:10. 1016/j. psym. 2014. 09. 008.
77. Di Rocco A, Brannan T, Prikhojan A, Yahr MD. Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm 1998;105:247-251.
78. Posada IJ, Lopez-Valdes E, Vallejo AR, Portera A. Extrapyramidal side effects and serotonin syndrome with fluoxetine and biperiden. Neurologia. 1998;13:405.
79. Gonul AS, Aksu M. SSRI-induced parkinsonism may be an early sign of future Parkinson's disease. J Clin Psychiatry. 1999;60:410.
80. Conforti D, Borgherini G, Fiorellini Bernardis LA, Magni G. Extrapyramidal symptoms associated with the adjunct of nortriptyline to a venlafaxine-valproic acid combination. Int Clin Psychopharmacol. 1999;14:197-198.
81. Stadtland C, Erfurth A, Arolt V. De novo onset of Parkinson's disease after antidepressant treatment with citalopram. Pharmacopsychiatry. 2000;33:194-195.
82. Gregory RJ, White JF. Can sertraline induce Parkinson's disease? Psychosomatics. 2001;42:163-164.
83. Pina Latorre MA, Modrego PJ, Rodilla F, Catalan C, Calvo M. Parkinsonism and Parkinson's disease associated with long-term administration of sertraline. J Clin Pharm Ther. 2001;26:111-112.
84. Arai M. Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran. J Neurol Neurosurg Psychiatry. 2003;74:137-138.
85. Bhanji NH, Margolese HC. Extrapyramidal symptoms related to adjunctive nizatidine therapy in an adolescent receiving quetiapine and paroxetine. Pharmacotherapy. 2004;24:923-925.
86. Mendhekar DN, Benuiwal RP, Puri V. Parkinsonism and elevated lactic acid with sertraline. Can J Psychiatry. 2005;50:301.
87. Ozalp E, Soygur H, Cankurtaran ES, et al. Sertraline, escitalopram and tianeptine related abnormal movements but not with bupropion: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1337-1339.
88. Thwaites JH, Hutchinson C, Collins C. Neurotoxic reaction to citalopram. N Z Med J. 2006;119(1235):U2019.
89. Muraoka T, Oku E, Sugataka K, Yamada S. A case of severe parkinsonism associated with short-term treatment with milnacipran. Clin Neuropharmacol. 2008;31:299-300.
90. Kuloglu M, Caykoylu A, Ekinci O, Bayindirli D, Vural G, Deniz O. Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use. J Psychopharmacol. 2010;24:623-624.
91. Caixeta L. Fluoxetine associated with severe extrapyramidal symptoms in a patient with basal ganglia lesion. Rev Bras Psiquiatr. 2009;31:182-183.
92. Miletić V, Relja M. Citalopram-induced parkinsonian syndrome: case report. Clin Neuropharmacol. 2011;34:92-93.
93. Kim JH, Park J, Yu KH, et al. Prodromal dementia with Lewy bodies manifesting as sertraline-induced parkinsonism: a case report. Alzheimer Dis Assoc Disord. 2012;26:191-193.
94. Ak S, Anil Yagcioglu AE. Escitalopram-induced parkinsonism. Gen Hosp Psychiatry. 2014;36:126. e1-126. e2.
95. Bates GD, Khin-Maung-Zaw F. Movement disorder with fluoxetine. J Am Acad Child Adolesc Psychiatry. 1998;37: 14-15.
96. Bronner IM, Vanneste JA. Complex movement disorder associated with fluvoxamine. Mov Disord. 1998;13:848-850.
97. Diler RS, Yolga AY, Avci A. Fluoxetine-induced extrapyramidal symptoms in an adolescent: a case report. Swiss Med Wkly. 2002;132:125-126.
98. Tarlaci S. Citalopram-induced jaw tremor. Clin Neurol Neurosurg. 2004;107:73-75.
99. Chen JJ, Swope DM. A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A. J Clin Psychiatry. 2005;66: 267-268.
100. Gray JA. Parkinsonism and rabbit syndrome after discontinuation of low-dose ziprasidone and concomitant initiation of sertraline. J Clin Psychopharmacol. 2012;32:142-143.
101. John P, McConnell K, Saif MW. Chin tremors associated with paroxetine in a patient with pancreatic adenocarcinoma. JOP. 2013;14:661-663.
102. Geber C, Ostad Haji E, Schlicht K, Hiemke C, Tadic A. Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder. Ther Drug Monit. 2013;35: 279-282.
103. Amiri ND, Wijenaike N. Citalopram-induced hyponatremia and parkinsonism: potentially fatal side-effects [published online November 12, 2014]. BMJ Case Rep. 2014. doi:10. 1136/bcr-2014-206575.
104. Halperin JR, Murphy B. Extrapyramidal reaction to ondansetron. Cancer. 1992;69:1275.
105. Sprung J, Choudhry FM, Hall BA. Extrapyramidal reactions to ondansetron: cross-reactivity between ondansetron and prochlorperazine. Anesth Analg. 2003;96:1374-1376.
106. Risperdal prescribing information. Titusville, NJ: Janssen Pharmaceuticals; 2014. http://www. janssenpharmaceuticalsinc. com/assets/risperdal. pdf. Accessed April 6, 2015.
107. Zyprexa prescribing information. Indianapolis, IN: Lilly USA; 2014. http://pi. lilly. com/us/zyprexa-pi. pdf. Accessed April 6, 2015.